Posts By :

Mea Holm, PhD

Mea Holm, PhD

Treating nature with NURTURE: Interim results of nusinersen for SMA

3473 2300 Mea Holm, PhD

Promising results for a disease-modifying treatment for spinal muscular atrophy (SMA) were presented at the 5th Annual Congress of the European Academy of Neurology (EAN) in Oslo, Norway, last week.…

read more

Cellular power failures linked to Parkinsonism

3150 2100 Mea Holm, PhD

Mounting evidence is linking neurodegenerative disorders, such as Parkinsonism and dementia, with mitochondrial dysfunction.1 At the 5th Annual Congress of the European Academy of Neurology (EAN) in Oslo, Norway, the…

read more

Gene therapy shows promise in Parkinson’s disease

2100 1400 Mea Holm, PhD

Interim results from a Phase Ib trial show that gene therapy may reduce the need for medication in patients with Parkinson’s disease refractory to levodopa. The investigational therapy is designed…

read more

Cognitive impairment in MS

2048 1153 Mea Holm, PhD

Up to 70% of MS patients suffer from cognitive decline, which often has a profound impact on an individual’s quality of life. It is little surprise that MS researchers are…

read more

Serum neurofilament light: A biomarker for disease activity in MS

1920 1080 Mea Holm, PhD

How close are we to establishing a reliable liquid biomarker for detecting disease onset, progression and treatment response in multiple sclerosis? According to Dr Peter Calabresi (Johns Hopkins, USA) at…

read more

Results from the MS-SMART trial unveiled

3971 2975 Mea Holm, PhD

Secondary progressive multiple sclerosis (SPMS) is known to be extremely difficult to treat; there are no effective therapies for halting or reversing disability progression in the late disease phase. In…

read more

Fighting neurodegeneration in MS

3150 2100 Mea Holm, PhD

The pathology of multiple sclerosis (MS) involves not only the loss of myelin sheets around the axons of neurons, but also the fragmentation of the axons themselves. At ECTRIMS 2018,…

read more

MS treatment strategy: Hitting hard and early, or minimising risks through stepwise escalation?

1969 1525 Mea Holm, PhD

With more than a dozen approved treatment options for relapsing-remitting multiple sclerosis (RRMS), treatment decision making is an increasingly complex task for neurologists. At ECTRIMS 2018, the topic on which…

read more

Gut feelings on MS: A conversation with Prof. Pot

2359 1740 Mea Holm, PhD

How does the gut–brain axis influence neuro-inflammation and the disease course of MS? Although we know that gut homeostasis and gut functions are closely related to food intake, we want…

read more

At the cutting edge of neurosurgery – A conversation with Dr Kienzler

1920 1280 Mea Holm, PhD

We met with Dr Jenny Kienzler – who recently won the first prize from the Swiss Neurosurgical Society – to talk about some hot topics in neurosurgery. Dr Kienzler is…

read more
Brainwork is supported by unrestricted grants from: